Chronic lymphocytic leukemia in young (≤ 55 years) patients: A comprehensive analysis of prognostic factors and outcomes

Haematologica

Volumn 99, Issue 1, 2014, Pages 140-147

  Parikh, Sameer A ^a   Rabe, Kari G ^a   Kay, Neil E ^a   Call, Timothy G ^a   Ding, Wei ^a   Schwager, Susan M ^a   Bowen, Deborah A ^a   Conte, Michael ^a   Jelinek, Diane F ^b   Slager, Susan L ^a   Shanafelt, Tait D ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892578245     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.086066     Document Type: Article

References (39)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
2. Abrisqueta P, Pereira A, Rozman C, Aymerich M, Gine E, Moreno C, et al. Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience. Blood. 2009; 114(10):2044-2050.
3. Brenner H, Gondos A, Pulte D. Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood. 2008;111(10): 4916-4921.
4. Call TG, Phyliky RL, Noel P, Habermann TM, Beard CM, O'Fallon WM, et al. Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis. Mayo Clinic Proceedings Mayo Clinic. 1994;69(4):323-328.
5. Ferrajoli A. Treatment of younger patients with chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2010;82-89.
6. Bennett JM, Raphael B, Oken MM, Rubin P, Silber R. The prognosis and therapy of chronic lymphocytic leukemia under age 50 years. Nouv Rev Fr Hematol. 1988;30(5-6):411-412.
7. Mauro FR, Foa R, Giannarelli D, Cordone I, Crescenzi S, Pescarmona E, et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood. 1999;94(2):448-454.
8. Molica S, Brugiatelli M, Callea V, Morabito F, Levato D, Nobile F, et al. Comparison of younger versus older B-cell chronic lympho-cytic leukemia patients for clinical presentation and prognosis. A retrospective study of 53 cases. Eur J Haematol. 1994;52(4):216-221.
9. Montserrat E, Gomis F, Vallespi T, Rios A, Romero A, Soler J, et al. Presenting features and prognosis of chronic lymphocytic leukemia in younger adults. Blood. 1991;78(6):1545-1551.
10. Dhodapkar M, Tefferi A, Su J, Phyliky RL. Prognostic features and survival in young adults with early/intermediate chronic lym-phocytic leukemia (B-CLL): a single institution study. Leukemia. 1993;7(8):1232-1235.
11. De Rossi G, Mandelli F, Covelli A, Luciani M, Martelli M, Resegotti L, et al. Chronic lymphocytic leukemia (CLL) in younger adults: a retrospective study of 133 cases. Hematol Oncol. 1989;7(2):127-137.
12. Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007;25(35):5616-5623.
13. Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, et al. Phase III randomized study of bendamus-tine compared with chlorambucil in previously untreated patients with chronic lym-phocytic leukemia. J Clin Oncol. 2009;27 (26):4378-4384.
14. Wierda WG, Kipps TJ, Durig J, Griskevicius L, Stilgenbauer S, Mayer J, et al. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lym-phocytic leukemia. Blood. 2011;117(24): 6450-6458.
15. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJS, Bezares R F, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007;370 (9583):230-239.
16. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107(3):885-891.
17. Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007;25(7):793-798.
18. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophos-phamide in patients with chronic lympho-cytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-1174.
19. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA, et al. Long-term results of the fludarabine, cyclophosphamide, and rit-uximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112 (4):975-980.
20. Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2007;21(1): 12-17.
21. Sorror ML, Storer BE, Sandmaier BM, Maris M, Shizuru J, Maziarz R, et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allo-geneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol. 2008;26(30):4912-4920.
22. Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol. 2007;25 (7):799-804.
23. Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lympho-cytic leukemia: justification for risk-adapted therapy. J Clin Oncol. 2006;24(3): 437-443.
24. Ding W, Ferrajoli A. Evidence-based mini-review: the role of alkylating agents in the initial treatment of chronic lymphocytic leukemia patients with the 11q deletion. Hematology Am Soc Hematol Educ Program. 2010;90-92.
25. Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lympho-cytic leukemia. Hematology Am Soc Hematol Educ Program. 2010;481-488.
26. Maddocks-Christianson K, Slager SL, Zent CS, Reinalda M, Call TG, Habermann TM, et al. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. Br J Haematol. 2007;139(3):398-404.
27. Shanafelt TD, Rabe KG, Kay NE, Zent CS, Jelinek DF, Reinalda MS, et al. Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer. 2010;116(20):4777-4787.
28. Shanafelt TD, Geyer SM, Bone ND, Tschumper RC, Witzig TE, Nowakowski GS, et al. CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol. 2008;140(5):537-546.
29. de Lima M, O'Brien S, Lerner S, Keating MJ. Chronic lymphocytic leukemia in the young patient. Semin Oncol. 1998;25(1):107-116.
30. Pamuk G, Pamuk O, Soysal T, Ongören S, Başlar Z, Ferhanoǧlu B, et al. An overview of young CLL patients: a single-centre experience from Turkey. Haematologia (Budap). 2002;31(4):303-311.
31. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990-4997.
32. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17(12):3835-3849.
33. Shanafelt TD, Witzig TE, Fink SR, Jenkins RB, Paternoster SF, Smoley SA, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol. 2006;24(28):4634-4641.
34. Moreira J, Rabe KG, Cerhan JR, Kay NE, Wilson JW, Call TG, et al. Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls. Leukemia. 2012;27(1):136-141.
35. Thurmes P, Call T, Slager S, Zent C, Jenkins G, Schwager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2008;49(1):49-56.
36. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12): 5446-5456.
37. Therneau TMGP. Modeling Survival Data, Extending the Cox Model. Springer, New York, NY. 2000:274-275.
38. Therneau TOJ. Technical Report Number 63: Expected Survival Based on Hazard Rates. Technical Reports Rochester, MN: Mayo Clinic. 1999;1:26.
39. Rai K, Sawitsky A, Cronkite E, Chanana A, Levy R, Pasternack B. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219-234.